Articles aimed towards readers with some grounding in the biological/medical sciences.
TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.
UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.
One way senescent cells accumulate is when one senescent cell turns a neighboring cell senescent through SASP secretion. SRF scientists have discovered that these secondary senescent cells are resistant to the classic senolytic drugs. However, they have identified a new senolytic strategy that kills these senescent cells.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In the final installment of this 5-part series, we look at TAME itself: how it’s structured, how it’s justified, and how the results could impact the push for longevity therapeutics.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 4 of this 5-part series, we look at human data on metformin and neurodegenerative aging diseases.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 3 of this 5-part series, we look at human trials of metformin in prevention and treatment of cancer.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 2 of this 5-part series, we look at some of the human studies on metformin, including a flawed observational study that created the illusion that diabetics on metformin actually live longer than people without diabetes.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 1 of this 5-part series, we look at the animal studies underlying this idea.
In heterochronic parabiosis, joining the circulatory systems of young and old mice causes the older animal to recover some features of youth. The effect has been widely assumed to be driven by pro-youth factors in younger blood, but an alternative hypothesis is possible: that the procedure is instead diluting pro-aging factors in the older partner.
Q: When senolytic drugs cause senescent cells to die, other (younger) cells need to divide and take the place of the dead cells. This cell division causes telomere shortening, thus possibly creating new senescent cells. How is it that the process of killing senescent cells is not self-defeating if new senescent cells are being created? …
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
